Time-point | Efficacy parameter achieved | Intention-to-treat | Per protocol | ||||
---|---|---|---|---|---|---|---|
Initial combination scheme ETA + MTX | Standard consequent scheme with MTXa | p | Initial combination scheme ETA + MTX | Standard consequent scheme with MTXa | p | ||
12 | ACR30 | 33/35 (94.3%) | 20/33 (60.6%) | 0.001 | 33/34 (97.1%) | 20/32 (62.5%) | 0.001 |
24 | Wallace inactive disease | 11/35 (31.4%) | 11/33 (33.3%) | > 0.999 | 11/33 (33.3%) | 11/30 (36.7%) | 0.798 |
48 | Wallace inactive disease | 17/35 (48.6%) | 20/33 (60.6%) | 0.342 | 17/32 (53.1%) | 19/29 (65.5%) | 0.436 |
48 | Remission | 11/35 (31.4%) | 8/33 (24.2%) | 0.594 | 11/32 (34.4%) | 8/29 (27.6%) | 0.593 |